Human Insulin Inhalation Powder + Injectable insulin + Insulin Glargine

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus, Type 1

Conditions

Diabetes Mellitus, Type 1

Trial Timeline

Aug 1, 2006 โ†’ May 1, 2008

About Human Insulin Inhalation Powder + Injectable insulin + Insulin Glargine

Human Insulin Inhalation Powder + Injectable insulin + Insulin Glargine is a phase 3 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 1. The current trial status is completed. This product is registered under clinical trial identifier NCT00356109. Target conditions include Diabetes Mellitus, Type 1.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT00356109Phase 3Completed
NCT00127634Phase 3Completed